Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Other Accumulated Expenses (2022 - 2023)

PharmaCyte Biotech (PMCB) has disclosed Other Accumulated Expenses for 4 consecutive years, with $287310.0 as the latest value for Q3 2023.

  • On a quarterly basis, Other Accumulated Expenses fell 23.82% to $287310.0 in Q3 2023 year-over-year; TTM through Jul 2023 was $287310.0, a 23.82% decrease, with the full-year FY2023 number at $287310.0, down 23.82% from a year prior.
  • Other Accumulated Expenses was $287310.0 for Q3 2023 at PharmaCyte Biotech, roughly flat from $287310.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $467000.0 in Q1 2022 to a low of $287310.0 in Q1 2023.